1. Generics Bulletin
  2. >>Business

ANI ‘On The Cusp Of A Transformation’ Following Cortrophin Launch

Company Expects Up To $40m From The Product In 2022

 
• By Chloe Kent

ANI Pharmaceuticals appeared confident about its Cortrophin gel launch and integration of Novitium Pharma as it rounded up its Q1 results, but net losses have dampened the company’s share value.

Close up of ANI sign at their Canadian head office in Oakville
ANI's share price took a hit following losses related to commercial expenses. • Source: Shutterstock

With a “robust” research and development infrastructure in place, plus several launches and six fresh abbreviated new drug application filings under its belt, ANI Pharmaceuticals, Inc. appeared to be in high spirits as it rounded up its results for the first quarter of 2022.

The company’s net revenues reached $64.5m during the quarter, a year-on-year increase of 16.8% compared to $54.5m in 2021. It currently anticipates a net revenue for the year between $295m and $315m, $35m to $40m of which it expects to come from its recently-launched Cortrophin gel (repository corticotropin injection) 80 U/ml, an adrenocorticotropic hormone therapy indicated for the treatment of a range of chronic autoimmune disorders

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.